A Phase 3 interventional study of 9vHPV Vaccine in Genital Warts, Anal Cancer and Anal Intraepithelial Neoplasia, sponsored by Merck Sharp & Dohme LLC. Completed. Open to participants aged 16 Years to 26 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2018-11-27.
Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 3, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 10 studies testing Human Papillomavirus Recombinant Vaccine nonavalent in Condylomata Acuminata — 2 open to participants now, 4 under way, 3 of them phase 3. Human Papillomavirus Recombinant Vaccine nonavalent · Condylomata Acuminata.
Among the 10 studies testing Human Papillomavirus Recombinant Vaccine nonavalent in Condylomata Acuminata, this one is the 2nd largest by enrollment, is the only one that started in 2012, is one of 9 in phase 3, and was the 2nd registered.
116 studies on the registry are indexed under Condylomata Acuminata; 11 are open to participants now.
Browse Condylomata Acuminata studies →2 of the 10 studies testing Human Papillomavirus Recombinant Vaccine nonavalent in Condylomata Acuminata are open now, in 3 countries. Recruiting first, the newest first:
Shanghai Bovax Biotechnology Co., Ltd. · Sites in China
Ages 9–45 · Women only · Healthy volunteers
National Institute of Hygiene and Epidemiology, Vietnam · Sites in Australia, Vietnam
Ages 18–26 · Women only · Healthy volunteers
By country, each count listing its studies:
Human Papillomavirus Recombinant Vaccine nonavalent: first FDA approval 2014 (Gardasil 9). What it is approved for, and how studies give it, is on its page →
Of the 6 Condylomata Acuminata studies recruiting now, 1 sets no upper age limit and 5 stop at 75 or younger; 4 take children under 18; 5 take healthy volunteers.
This study: 16 Years to 26 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
10 studies; the count open now beside each. This study's row is marked.
First in 2010; this study’s year is marked. 1 started in 2012.
This study's enrollment of 2,520 is above the median of 158 across 95 interventional studies indexed under Condylomata Acuminata.
Median enrollment 1,206 across the 10 interventional studies. Of the 6 that completed or were terminated, 5 (83%) have results posted.
This tab as a report to print or save as PDF → With an account.
8 of 10 have an industry lead sponsor. The 4 most frequent:
This study is registered under Merck Sharp & Dohme LLC, one of the names counted as Merck & Co., Inc. Under that name alone:
Merck Sharp & Dohme LLC is the lead sponsor of 2,167 studies on the registry; 132 are open to participants now.
Of its 504 completed or terminated interventional studies of FDA-regulated products, 371 (74%) have results posted.
19 studies in Condylomata Acuminata by Merck & Co., Inc: none open now, 2 under way, 1 of them phase 3. Of 16 finished, 12 (75%) have results posted.
Among the 19 studies in Condylomata Acuminata by Merck & Co., Inc, this one is the 7th largest by enrollment of the 18 interventional ones that give a count, is the only one that started in 2012, is one of 14 in phase 3, and was the 14th registered.
Merck & Co., Inc’s Condylomata Acuminata studies by the year they started, since 2001.
None of the studies under way reaches primary completion within a year.
Among the 10 studies testing Human Papillomavirus Recombinant Vaccine nonavalent in Condylomata Acuminata, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Merck & Co., Inc’s 19 in Condylomata Acuminata:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study is designed to evaluate the immunogenicity and tolerability of 9vHPV (9-valent HPV vaccine, V503) in 16- to 26-year old men and women. The overall goal is to bridge 9vHPV efficacy findings in young women to young men based on the demonstration of similar immunogenicity and safety profiles. The primary hypothesis is that 9vHPV induces antibody responses at 4 weeks postdose 3 in heterosexual males that are non-inferior to antibody responses in young women.
Study participants will be administered a 3-dose regimen of 9vHPV. They will be assessed for immunogenicity 1 month following completion of vaccination. All participants will be followed for safety for a total of 12 months.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Healthy females 16 to 26 years of age received 9vHPV vaccine 0.5 mL intramuscular injection on Day 1, Month 2, and Month 6
Biological: 9vHPV Vaccine
Healthy heterosexual males 16 to 26 years of age received 9vHPV 0.5 mL intramuscular injection on Day 1, Month 2, and Month 6
Biological: 9vHPV Vaccine
Healthy MSM 16 to 26 years of age received 9vHPV 0.5 mL intramuscular injection on Day 1, Month 2, and Month 6
Biological: 9vHPV Vaccine
9vHPV, V503 (9-valent HPV \[Types 6, 11, 16, 18, 31, 33, 45, 52, and 58\] L1 virus-like particle vaccine), 0.5 mL injection in 3-dose regimen
Geometric Mean Titers (GMTs) to the HPV Types Contained in the 9vHPV Vaccine
Serum antibodies to HPV types 6/11/16/18/31/33/45/52/58 were measured with a Competitive Luminex Immunoassay. Titers are reported in milli Merck Units/mL
Time frame: Four weeks post vaccination 3 (Month 7)
Percentage of Participants With One or More Injection-site Adverse Experiences Prompted on the Vaccination Report Card
An adverse experience (AE) is defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the study vaccine, whether or not considered related to the use of the product. Any worsening of a preexisting condition which is temporally associated with the use of the study vaccine is also an AE. Injection-site AEs prompted on the Vaccination Report Card (VRC) were erythema, pain, and swelling. Participants were instructed to use the Vaccination Report Card to record AEs daily after each study vaccination.
Time frame: Up to 5 days after any vaccination
Percentage of Participants With Elevated Oral Body Temperature (>=37.8° C, >=100° F)
Participants were instructed by the investigator to use the Vaccination Report Card to document evening oral temperature daily after each study vaccination
Time frame: Up to 5 days after any vaccination
Percentage of Participants With an Adverse Event
An AE is defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the study vaccine, whether or not considered related to the use of the product. Any worsening of a preexisting condition which is temporally associated with the use of the study vaccine is also an AE.
Time frame: Up to Month 12
Percentage of Participants Who Had Study Vaccine Discontinued Due to an Adverse Event
An AE is defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the study vaccine, whether or not considered related to the use of the product. Any worsening of a preexisting condition which is temporally associated with the use of the study vaccine is also an AE.
Time frame: Up to Month 12
Percentage of Participants With Seroconversion to the HPV Types Contained in the 9vHPV Vaccine
Serum antibodies to HPV types were measured with a Competitive Luminex Immunoassay. The serostatus cutoffs (milli Merck U/mL) for HPV types were as follows: HPV Type 6: ≥30; HPV Type 11: ≥16; HPV Type 16: ≥20; HPV Type 18: ≥24; HPV Type 31: ≥10; HPV Types 33, 45, 52, and 58: ≥8.
Time frame: Four weeks post vaccination 3 (Month 7)
| Milestone | Heterosexual Males | Females | Men Who Have Sex With Men (MSM) |
|---|---|---|---|
| Started | 1106 | 1101 | 313 |
| Vaccination 1 | 1103 | 1099 | 313 |
| Vaccination 2 | 1089 | 1069 | 298 |
| Vaccination 3 | 1067 | 1037 | 291 |
| Completed | 1053 | 1015 | 282 |
| Not completed | 53 | 86 | 31 |
| Withdrew: Unknown status | 4 | 4 | 0 |
| Withdrew: Lost to follow-up | 30 | 56 | 20 |
| Withdrew: Protocol violation | 0 | 2 | 1 |
| Withdrew: Physician decision | 0 | 2 | 0 |
| Withdrew: Adverse event | 0 | 2 | 1 |
| Withdrew: Screen failure | 2 | 2 | 0 |
| Withdrew: Withdrawal by subject | 17 | 18 | 9 |
Serum antibodies to HPV types 6/11/16/18/31/33/45/52/58 were measured with a Competitive Luminex Immunoassay. Titers are reported in milli Merck Units/mL
| milli Merck Units/mL | Heterosexual Males | Females | Men Who Have Sex With Men |
|---|---|---|---|
| Anti-HPV Type 6 (n=847, 708, 164) | 782.0 (738.0 to 828.7) | 703.9 (660.6 to 749.9) | 568.9 (498.7 to 649.0) |
| Anti-HPV Type 11 (n=851, 712, 165) | 616.7 (582.4 to 653.0) | 564.9 (530.6 to 601.3) | 437.7 (384.4 to 498.5) |
| Anti-HPV Type 16 (n=899, 781, 212) | 3346.0 (3158.9 to 3544.1) | 2788.3 (2621.4 to 2965.8) | 2294.0 (2037.8 to 2582.5) |
| Anti-HPV Type 18 (n=906, 831, 220) | 808.2 (754.9 to 865.4) | 679.8 (633.1 to 730.1) | 608.1 (529.4 to 698.5) |
| Anti-HPV Type 31 (n=908, 826, 227) | 708.5 (662.7 to 757.6) | 570.1 (531.5 to 611.5) | 420.7 (368.0 to 480.9) |
| Anti-HPV Type 33 (n=901, 853, 230) | 384.8 (362.5 to 408.4) | 322.0 (302.9 to 342.3) | 252.3 (224.2 to 283.8) |
| Anti-HPV Type 45 (n=909, 871, 232) | 235.6 (219.0 to 253.6) | 185.7 (172.3 to 200.2) | 157.5 (136.2 to 182.2) |
| Anti-HPV Type 52 (n=907, 849, 232) | 386.8 (363.4 to 411.6) | 335.2 (314.3 to 357.6) | 233.1 (206.0 to 263.7) |
| Anti-HPV Type 58 (n=897, 839, 223) | 509.8 (479.9 to 541.6) | 409.3 (384.5 to 435.7) | 319.8 (283.2 to 361.0) |
An adverse experience (AE) is defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the study vaccine, whether or not considered related to the use of the product. Any worsening of a preexisting condition which is temporally associated with the use of the study vaccine is also an AE. Injection-site AEs prompted on the Vaccination Report Card (VRC) were erythema, pain, and swelling. Participants were instructed to use the Vaccination Report Card to record AEs daily after each study vaccination.
| Percentage of Participants | Heterosexual and MSM Males | Females |
|---|---|---|
| Overall injection-site AEs | 66.7 | 84.0 |
| Injection-site Erythema | 20.7 | 32.2 |
| Injection-site Pain | 63.4 | 82.5 |
| Injection-site Swelling | 20.2 | 37.5 |
Participants were instructed by the investigator to use the Vaccination Report Card to document evening oral temperature daily after each study vaccination
| Percentage of Participants | Heterosexual and MSM Males | Females |
|---|---|---|
| Percentage of Participants With Elevated Oral Body Temperature (>=37.8° C, >=100° F) | 4.4 | 5.9 |
Serum antibodies to HPV types were measured with a Competitive Luminex Immunoassay. The serostatus cutoffs (milli Merck U/mL) for HPV types were as follows: HPV Type 6: ≥30; HPV Type 11: ≥16; HPV Type 16: ≥20; HPV Type 18: ≥24; HPV Type 31: ≥10; HPV Types 33, 45, 52, and 58: ≥8.
| Percentage of Participants | Heterosexual Males | Females | Men Who Have Sex With Men |
|---|---|---|---|
| Anti-HPV Type 6 (n=847, 708, 164) | 99.6 (99.0 to 99.9) | 99.6 (98.8 to 99.9) | 99.4 (96.6 to 100) |
| Anti-HPV Type 11 (n=851, 712, 165) | 100 (99.6 to 100) | 99.9 (99.2 to 100) | 100 (97.8 to 100) |
| Anti-HPV Type 16 (n=899, 781, 212) | 100 (99.6 to 100) | 99.9 (99.3 to 100) | 100 (98.3 to 100) |
| Anti-HPV Type 18 (n=906, 831, 220) | 99.9 (99.4 to 100) | 99.8 (99.1 to 100) | 99.5 (97.5 to 100) |
| Anti-HPV Type 31 (n=908, 826, 227) | 100 (99.6 to 100) | 100 (99.6 to 100) | 100 (98.4 to 100) |
| Anti-HPV Type 33 (n=901, 853, 230) | 100 (99.6 to 100) | 99.9 (99.3 to 100) | 100 (98.4 to 100) |
| Anti-HPV Type 45 (n=909, 871, 232) | 99.8 (99.2 to 100) | 99.5 (98.8 to 99.9) | 100 (98.4 to 100) |
| Anti-HPV Type 52 (n=907, 849, 232) | 100 (99.6 to 100) | 99.8 (99.2 to 100) | 100 (98.4 to 100) |
| Anti-HPV Type 58 (n=897, 839, 223) | 100 (99.6 to 100) | 99.8 (99.1 to 100) | 100 (98.4 to 100) |
An AE is defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the study vaccine, whether or not considered related to the use of the product. Any worsening of a preexisting condition which is temporally associated with the use of the study vaccine is also an AE.
| Percentage of Participants | Heterosexual and MSM Males | Females |
|---|---|---|
| Percentage of Participants With an Adverse Event | 76.2 | 89.4 |
An AE is defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the study vaccine, whether or not considered related to the use of the product. Any worsening of a preexisting condition which is temporally associated with the use of the study vaccine is also an AE.
| Percentage of Participants | Heterosexual and MSM Males | Females |
|---|---|---|
| Percentage of Participants Who Had Study Vaccine Discontinued Due to an Adverse Event | 0.1 | 0.3 |
Collected over Up to Month 12. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Heterosexual and MSM Males | — | 23/1,394 (1.6%) | 976/1,394 (70%) |
| Females | — | 26/1,075 (2.4%) | 924/1,075 (86%) |
| Event | Heterosexual and MSM Males | Females |
|---|---|---|
| Abortion spontaneousPregnancy, puerperium and perinatal conditions | 0/1394 | 4/1075 |
| Abortion inducedSurgical and medical procedures | 0/1394 | 4/1075 |
| ConstipationGastrointestinal disorders | 0/1394 | 2/1075 |
| Ectopic pregnancyPregnancy, puerperium and perinatal conditions | 0/1394 | 2/1075 |
| AppendicitisInfections and infestations | 2/1394 | 1/1075 |
| ConcussionInjury, poisoning and procedural complications | 2/1394 | 0/1075 |
| VomitingGastrointestinal disorders | 0/1394 | 1/1075 |
| Cyst ruptureGeneral disorders | 0/1394 | 1/1075 |
| CholecystitisHepatobiliary disorders | 0/1394 | 1/1075 |
| Appendicitis perforatedInfections and infestations | 0/1394 | 1/1075 |
| Event | Heterosexual and MSM Males | Females |
|---|---|---|
| Injection site painGeneral disorders | 886/1394 | 893/1075 |
| Injection site swellingGeneral disorders | 285/1394 | 408/1075 |
| Injection site erythemaGeneral disorders | 291/1394 | 348/1075 |
| HeadacheNervous system disorders | 200/1394 | 246/1075 |
| Age, Continuous(Years) | Heterosexual Males | Females | Men Who Have Sex With Men (MSM) | Total |
|---|---|---|---|---|
| Mean | 20.8 ± 3.0 | 21.3 ± 2.9 | 22.2 ± 2.4 | 21.2 ± 2.9 |
| Sex: Female, Male(Participants) | Heterosexual Males | Females | Men Who Have Sex With Men (MSM) | Total |
|---|---|---|---|---|
| Female | 0 | 1101 | 0 | 1101 |
| Male | 1106 | 0 | 313 | 1419 |
No study locations are listed for this record.
Plan to share: Yes — https://www.merck.com/clinical-trials/pdf/ProcedureAccessClinicalTrialData.pdf
Data sharing details ↗ · engagezone.msd.com
Ran from Oct 2012 to primary completion in Aug 2014, 21 months.
Results were first posted in Mar 2015, 7 months after primary completion.
Of 28 phase 3 interventional studies under Condylomata Acuminata, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 61. This study's 21 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Human Papillomavirus Recombinant Vaccine nonavalent